AOD-9604 Protocol: How to Cycle It, Timing & What to Expect

Protocol snapshot

• Typical cycle length: 8 to 12 weeks standard; some protocols extend to 16 to 24 weeks for gradual responders, followed by a 4-week off-cycle break (practitioner standard) or continuous use (clinical trial standard)
• Frequency: Once daily in the morning, fasted; an advanced approach divides the daily amount into a morning and early-afternoon administration roughly six hours apart
• Common delivery routes: Subcutaneous injection (primary, evidence-based); oral and intranasal routes exist in some protocols with limited supporting data
• Key timing notes: Morning fasted, 30 to 60 min pre-meal

Who This Protocol Is For

AOD-9604 draws interest from people who want to address body composition, specifically fat loss, without the hormonal profile of full growth hormone. It is the C-terminal fragment of human growth hormone (amino acids 176 to 191), designed to isolate the lipolytic, meaning fat-mobilizing, activity of hGH while leaving the hormonal and metabolic effects behind. It does not meaningfully raise IGF-1, does not suppress natural hormone production, and does not interfere with insulin sensitivity. For people who want targeted fat-metabolism support without those tradeoffs, that profile is the appeal.

The most common use cases are general fat loss paired with a caloric deficit, stubborn body composition goals after a training plateau, and body recomposition where someone wants to preserve muscle while reducing fat mass. It is also looked at by people who have tried dietary changes and exercise but want additional metabolic support during a structured cut.

Experience level shapes how the protocol is approached. Newer users tend to start at the more conservative end of the titration approach and pay close attention to timing and fasting discipline before anything else. More experienced users who have already dialed in nutrition and training may move to the higher end of the range more confidently from early in the cycle.

One thing that consistently separates people who see meaningful results from those who do not is adherence to fasted-state administration paired with a caloric deficit. AOD-9604 is not a standalone fat-loss solution. It works within a protocol that includes diet and exercise, and readers should be clear on that going in.

A note on delivery route: the clinical data supporting AOD-9604 comes from the subcutaneous route. Oral and intranasal options exist in some protocols, but the evidence behind them is considerably thinner. AOD-9604 is not the strongest choice for someone who wants a well-supported non-injectable alternative.

How Is an AOD-9604 Cycle Structured?

The shape of a standard AOD-9604 cycle is a multi-week daily-injection sequence organized as a titration phase followed by a steady maintenance phase, then an off-cycle break depending on the approach used.

Most protocols run 8 to 12 weeks as the core cycle. Clinical trials have run continuous daily use for 12 to 24 weeks, establishing that duration as both viable and well-tolerated. Eight weeks is generally considered the minimum meaningful assessment period; 12 to 16 weeks is where most people doing a full evaluation land. The cycle is daily throughout. Consistency matters because fat mobilization is a cumulative process, and the compound needs stable daily presence to sustain its effect on adipose tissue.

The three phases are a titration phase covering the first several weeks, a maintenance phase for the remainder of the cycle, and an off-cycle break if the practitioner approach is used. The titration phase starts conservatively and steps up to the target level, not the other way around. The full mechanics of each phase, including the important point about dose consistency across titration and maintenance, are covered in the Loading and Maintenance Phases section below.

How Your Dose Is Determined

What moves an AOD-9604 dose:

• Your goal: Fat-loss maintenance and gradual recomposition sit toward the more conservative end of the range. Accelerated fat loss during a structured cut tends to sit toward the higher end. Some users also consider whether to run a single morning administration or divide the daily amount into a morning and early-afternoon split, which influences how the daily total is structured.
• Experience level: Newer users and those who have not run peptide protocols before typically start more conservatively and hold there through the titration window, adjusting based on how the body responds. More experienced users with structured nutrition and training programs tend to move to the higher end more confidently.
• Delivery route: The subcutaneous route is the evidence-based standard and the baseline against which the dose range is built. Oral and intranasal routes involve meaningfully different dose considerations that do not translate directly from the subcutaneous range.
• Individual response: Two people with the same goal and experience level can have noticeably different responses. Baseline body composition, metabolic rate, adherence to fasted-state administration, and whether a caloric deficit is maintained all influence how much the compound does. There is no single number that works for everyone.

What makes AOD-9604 distinct is that fasted-state administration and dietary discipline function almost as co-variables alongside the dose itself. Someone taking the same daily amount but skipping the fasting window will likely see a fraction of the effect compared to someone who is consistent with morning fasted dosing. The dose amount matters, but it works inside a protocol structure, and that full structure is what a personalized plan accounts for.

Your dose should not be a guess. The MyPeptidePal Protocol Creator takes your fat-loss goal, your preferred delivery route, and whether you run a single morning dose or an advanced split administration and builds your AOD-9604 protocol: your dose, your cycle, and your timing.

Get your protocol at mypeptidepal.ai

How Often Do You Take AOD-9604?

AOD-9604 is typically taken once daily, with morning fasted-state administration as the standard across both clinical protocols and real-world use. The compound's lipolytic activity is most pronounced when insulin levels are low and the body is in a fat-burning state. An overnight fast of 8 to 10 hours sets that context, and a 30 to 60 minute window before the first meal extends it. Taking the peptide in a fed state blunts the fat-mobilization effect significantly. Users who skip the fasting window consistently report weaker outcomes, making this the single most important timing variable in the protocol.

Pre-exercise timing adds another layer. Taking AOD-9604 before fasted cardio creates a window where elevated fat mobilization from the peptide aligns with elevated energy demand from exercise. Many users structure their morning around this sequence: wake, administer, wait 30 to 40 minutes, then train fasted, then eat. It is not mandatory, but it fits the mechanism well.

An advanced twice-daily approach exists for users looking to maintain more consistent lipolytic activity across the full day. In this pattern, the daily amount is divided into a morning administration and an early-to-late afternoon administration roughly six hours apart. This divides the existing daily total into two smaller administrations rather than adding to it. Evening dosing is generally avoided because some users report difficulty with sleep onset when the compound is taken too close to bedtime.

Daily consistency matters more than exact clock time. Rotating injection sites across the abdomen, thighs, and upper arms prevents lipohypertrophy, the localized tissue hardening that develops when the same spot is used repeatedly and impairs absorption over time.

Loading and Maintenance Phases

AOD-9604 uses a titration structure rather than a traditional loading phase, and the distinction is worth understanding clearly. A loading phase in many peptide protocols means starting at the same dose you will maintain, or occasionally front-loading a higher amount early. AOD-9604 goes the other direction: the titration phase starts more conservatively in the first weeks, allowing the body to adapt, then steps up to the target maintenance level for the remainder of the cycle.

During the titration phase, which covers the first several weeks, the daily dose is held at the more conservative end of the range. This window is about establishing consistent daily use and letting the body adapt before moving to the target amount. Mild side effects, mostly injection-site reactions and occasional GI discomfort, are more likely to surface during this adaptation window. Starting conservatively reduces that likelihood and gives you a clear read on individual response before stepping up.

The maintenance phase covers the bulk of the cycle. Once the target level is reached, it stays steady for the remainder of the run. There is no progressive escalation during maintenance. The goal is stable, consistent daily presence at the appropriate level for your goal. Importantly, the dose does not increase at the end of a cycle or peak at any particular week. Stability and timing discipline, particularly fasted-state administration, do more for outcomes across the full cycle than pushing the dose higher at any point.

Clinical trials that established the safety and efficacy profile for AOD-9604 used this steady continuous daily approach across 12 to 24 weeks, and the protocol structure reflects that model.

Off-Cycle Considerations

The off-cycle question for AOD-9604 does not have a single clean answer, because the published clinical data and the practitioner consensus do not fully agree.

Clinical trials ran continuous daily administration for 12 to 24 weeks without finding receptor downregulation, tolerance development, or a biological need for breaks. AOD-9604 does not suppress natural hormone production and does not create the kind of feedback-loop disruption that would make a rest period physiologically necessary based on the available data.

Practitioner consensus takes a more cautious position. A common recommendation in clinical and wellness practice is a four-week break after a 12-week cycle before reassessing. The rationale is precautionary: in the absence of long-term human data beyond the clinical trial windows, building in a rest period is considered prudent. Some practitioners use a 12-weeks-on, 4-to-8-weeks-off structure as their standard approach.

Both approaches, continuous use for 12 to 24 weeks and cycling with a four-week break, are reasonable and defensible. The continuous approach is more consistent with the published trial data. The cycling approach reflects the precautionary stance many practitioners prefer when long-term data is limited.

One clarification that matters for users who hit a plateau around weeks 10 to 12: that slowdown is a normal adaptive response as the body approaches a new equilibrium, not a sign of receptor fatigue. Recognizing the difference prevents premature decisions to cycle off or abandon the protocol before the full cycle is complete.

What to Expect Week by Week

• Week 1 to 2: Most users notice very little visually during this window. The scale may fluctuate normally. Some report a mild warmth at the injection site for 15 to 30 minutes post-injection, which typically settles as the body adapts. Energy during fasted cardio may feel marginally improved. The compound is working at the metabolic level, but visible results are not yet present.
• Week 3 to 4: Early indicators begin to emerge for some users. The scale may shift slightly. Clothes may fit marginally looser around the waist. Fasted cardio performance often continues to improve. This is still early, and expecting significant visual change in this window leads to frustration. The trajectory is becoming established.
• Week 5 to 8: The first real visible changes typically appear for consistent users who are maintaining a caloric deficit and fasted dosing. Waist measurements begin to drop noticeably. Progress photos taken at week four and week eight often reveal changes that the mirror does not easily capture day to day.
• Beyond 8 weeks: Weeks 8 to 12 are where most clinical and community data converges on meaningful fat-loss outcomes. A 24-week Stier et al. (2004) clinical trial found roughly 5 to 6 pounds of additional fat loss versus placebo at the highest studied dose; at the standard daily range, the effect size is more modest. The rate of change tends to slow somewhat after week 12 as the body adapts, which is normal rather than a signal that the compound has stopped working.

These are commonly reported ranges drawn from clinical data and real-world protocols, not guarantees. Individual results vary by dietary adherence, training consistency, delivery timing, and individual metabolic response. A well-structured 12-week run with consistent fasted dosing, a sustainable caloric deficit, and regular training represents the realistic arc of what a disciplined cycle looks like: steady, compounding fat-mass reduction across the full cycle rather than dramatic change concentrated in any single week.

Common Protocol Mistakes

Dosing in a fed state. The most common reason users see disappointing results is taking AOD-9604 after eating or without adequate fasting time. The lipolytic effect depends on low insulin levels. Morning fasted administration with a 30 to 60 minute pre-meal window is a core protocol requirement, not optional context.

Running the cycle too short. Eight weeks is the minimum meaningful assessment period, and 12 weeks is where most data is collected. Users who run four to six week cycles and conclude the compound does not work have not allowed enough time. Fat-loss processes are gradual by nature, and cutting the cycle short before visible results appear produces a false conclusion about efficacy.

Inconsistent daily timing. AOD-9604 works through consistent daily presence. Missed days and irregular timing interrupt that consistency. A missed dose should simply be skipped rather than doubled the next day; doubling does not restore the missed effect and increases the risk of GI side effects.

Shaking the vial during reconstitution. Vigorous shaking denatures the peptide and renders the solution inactive. Discard any solution that appears cloudy or contains visible particles before injecting. Follow the reconstitution guidance in your personalized protocol from the Protocol Creator.

Confusing micrograms with insulin units. Insulin syringes are marked in IU on a 0.01 to 1.0 scale. AOD-9604 doses are in micrograms. Treating a microgram dose as though it maps directly onto insulin units produces tenfold dosing errors.

Not rotating injection sites. Using the same abdominal site daily causes lipohypertrophy, localized hardened tissue that impairs absorption and makes injections increasingly uncomfortable. Rotating daily across the abdomen, thighs, and upper arms keeps tissue healthy and maintains consistent absorption.

AOD-9604 is not FDA-approved for human use in the United States and is classified as an investigational compound. Athletes subject to WADA testing should verify its status under applicable sports regulations before beginning a protocol.

Frequently Asked Questions

How long is a typical AOD-9604 cycle?

Most protocols run 8 to 12 weeks as the standard cycle, with 12 weeks representing the most common benchmark drawn from clinical trial data. Some practitioners extend cycles to 16 to 24 weeks for gradual responders or significant body composition goals. Eight weeks is the minimum meaningful window for assessing results; shorter cycles rarely give the compound enough time to produce visible change.

How often do you take AOD-9604?

AOD-9604 is typically taken once daily in the morning, on an empty stomach, 30 to 60 minutes before the first meal. This fasted-state timing is the most critical protocol variable, because the compound's fat-mobilizing activity is most effective when insulin levels are low. An advanced approach divides the daily amount into a morning and early-afternoon administration, roughly six hours apart, for more consistent activity across the day.

Does AOD-9604 need a loading phase?

AOD-9604 uses a titration structure rather than a traditional loading phase. The protocol starts at a more conservative dose for the first several weeks to allow the body to adapt, then steps up to the target maintenance level for the remainder of the cycle. The purpose is adaptation and tolerance assessment, not front-loading the compound at a higher starting amount.

Do you need to cycle off AOD-9604?

There is no published evidence of receptor downregulation or tolerance development that makes cycling off biologically necessary. Clinical trials ran continuous daily use for 12 to 24 weeks without finding a need for breaks. That said, many practitioners recommend a four-week off-cycle break after a 12-week run as a precautionary measure given limited long-term human data, and both continuous and cycled approaches appear in real-world protocols.

Does AOD-9604 affect hormones or IGF-1?

No. AOD-9604 is engineered to isolate the fat-mobilizing region of human growth hormone without carrying its hormonal activity. It does not meaningfully raise IGF-1, does not suppress natural hormone production, and does not interfere with insulin sensitivity or glucose metabolism. This non-hormonal profile is one of the primary reasons people choose it over full growth hormone or other peptides with broader endocrine involvement.

Is fasted cardio required for AOD-9604 to work?

Fasted cardio is not strictly required, but it aligns closely with the mechanism and is consistently associated with better outcomes. AOD-9604 mobilizes fat from adipose tissue, and exercising in a fasted state creates a window where that mobilized fat is more readily used as fuel. A caloric deficit is the non-negotiable variable; fasted cardio amplifies the effect within that context.

Disclaimer

This content is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. MyPeptidePal is not a medical provider. Always consult a qualified healthcare professional before starting, modifying, or stopping any health protocol, supplement regimen, or therapeutic intervention.

Sources

The information in this guide is drawn from the MyPeptidePal knowledge base, which brings together published research, clinical data, and documented real-world protocols for AOD-9604 in one place.